LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
+3.1%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$1.39B
AUM Growth
+$1.39B
(+19%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
16.7%
Top 10 Holdings %
Top 10 Hldgs %
54.77%
Holding
73
New
16
Increased
17
Reduced
14
Closed
16
Top Buys
| 1 |
IDEAYA Biosciences
IDYA
|
$45.2M |
| 2 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$38M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$36.3M |
| 4 |
PMV Pharmaceuticals
PMVP
|
$35.6M |
| 5 |
BCYC
Bicycle Therapeutics
BCYC
|
$31.6M |
Top Sells
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$31.2M |
| 2 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$28.4M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$15.8M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$15.4M |
| 5 |
VERV
Verve Therapeutics
VERV
|
$14.8M |
Sector Composition
| 1 | Healthcare | 99.99% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Athira Pharma
ATHA
$15.5M
| $17.4M | 1.26% |
1,855,812
+445,000
| +32% | +$4.17M |
|
27
Century Therapeutics
IPSC
$40.4M
| $16.1M | 1.16% |
639,095
-350,000
| -35% | -$8.81M |
|
|
JNCE
28
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $14.9M | 1.07% |
+2,000,000
| New | +$14.9M |
|
29
Prelude Therapeutics
PRLD
$69.1M
| $12.5M | 0.9% |
400,000
| – | – |
|
|
30
Iovance Biotherapeutics
IOVA
$800M
| $12.3M | 0.89% |
500,000
-625,000
| -56% | -$15.4M |
|
31
Edgewise Therapeutics
EWTX
$1.54B
| $10.8M | 0.78% |
681,812
-550,000
| -45% | -$8.67M |
|
32
Biomea Fusion
BMEA
$114M
| $8.41M | 0.61% |
702,320
-460,000
| -40% | -$5.51M |
|
33
Eledon Pharmaceuticals
ELDN
$155M
| $8.28M | 0.6% |
1,339,793
| – | – |
|
34
ESSA Pharma
EPIX
$11.2M
| $8M | 0.58% |
+1,000,000
| New | +$8M |
|
35
Altimmune
ALT
$325M
| $7.92M | 0.57% |
+700,000
| New | +$7.92M |
|
36
Cogent Biosciences
COGT
$1.83B
| $7.78M | 0.56% |
925,000
-495,500
| -35% | -$4.17M |
|
|
BCEL
37
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $7.32M | 0.53% |
+1,175,000
| New | +$7.32M |
|
38
Tourmaline Bio
TRML
$645M
| $6.89M | 0.5% |
507,923
| – | – |
|
|
RAIN
39
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $6.61M | 0.48% |
465,331
-315,000
| -40% | -$4.48M |
|
40
Cullinan Oncology
CGEM
$456M
| $6.51M | 0.47% |
288,458
| – | – |
|
41
GH Research
GHRS
$870M
| $6.44M | 0.46% |
324,333
-400,000
| -55% | -$7.94M |
|
42
Janux Therapeutics
JANX
$1.38B
| $4.81M | 0.35% |
247,122
-300,000
| -55% | -$5.84M |
|
43
Synlogic
SYBX
$17.4M
| $4.58M | 0.33% |
+1,500,000
| New | +$4.58M |
|
|
ALPN
44
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $4.54M | 0.33% |
+425,000
| New | +$4.54M |
|
45
Shattuck Labs
STTK
$61.3M
| $4.08M | 0.29% |
+200,000
| New | +$4.08M |
|
|
IMA
46
ImageneBio, Inc. Common Stock
IMA
$153M
| $3.78M | 0.27% |
299,853
| – | – |
|
47
Day One Biopharmaceuticals
DAWN
$766M
| $2.8M | 0.2% |
52,069
+15,000
| +40% | +$806K |
|
48
Nuvalent
NUVL
$5.74B
| $2.73M | 0.2% |
+134,650
| New | +$2.73M |
|
|
SLGC
49
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $2.24M | 0.16% |
+200,493
| New | +$2.24M |
|
|
KNTE
50
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $2.17M | 0.16% |
94,345
-1,235,257
| -93% | -$28.4M |
|